Raj JD - Seelos Therapeutics Chairman, Founder
Insider
Raj JD is Chairman, Founder of Seelos Therapeutics
| Age | 64 |
| Phone | 646 293 2100 |
| Web | https://seelostherapeutics.com |
Seelos Therapeutics Management Efficiency
The company has return on total asset (ROA) of (2.6111) % which means that it has lost $2.6111 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.842) %, meaning that it created substantial loss on money invested by shareholders. Seelos Therapeutics' management efficiency ratios could be used to measure how well Seelos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Seelos Therapeutics currently holds 14.23 M in liabilities with Debt to Equity (D/E) ratio of 0.73, which is about average as compared to similar companies. Seelos Therapeutics has a current ratio of 3.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Seelos Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Seelos Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Seelos Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Seelos to invest in growth at high rates of return. When we think about Seelos Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Douglas Drysdale | Cybin Inc | 55 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Alexander Klibanov | Pulmatrix | 75 | |
| Robert Barrow | Mind Medicine | 36 | |
| Ray MD | Akari Therapeutics PLC | 79 | |
| MAICD MAICD | Opthea | 48 | |
| Aaqil Anwar | ATAI Life Sciences | N/A | |
| Matthew Gall | Iteos Therapeutics | 48 | |
| Anish MD | Soleno Therapeutics | 55 | |
| Annie Lee | Opthea | N/A | |
| Linda Marbn | Capricor Therapeutics | 62 | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
| Florian Brand | ATAI Life Sciences | 38 | |
| II MD | Entera Bio | 71 | |
| James MacKaness | Soleno Therapeutics | 61 | |
| RAC Sakai | Tempest Therapeutics | N/A | |
| Alan Russell | Edgewise Therapeutics | 55 | |
| John Kanakis | Cybin Inc | 44 | |
| CPA CPA | Opthea | 63 | |
| Joanne MD | Iteos Therapeutics | 52 | |
| Yvonne McGrath | Iteos Therapeutics | 51 | |
Management Performance
| Return On Equity | -5.84 | |||
| Return On Asset | -2.61 |
Seelos Therapeutics Leadership Team
Elected by the shareholders, the Seelos Therapeutics' board of directors comprises two types of representatives: Seelos Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Seelos. The board's role is to monitor Seelos Therapeutics' management team and ensure that shareholders' interests are well served. Seelos Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Seelos Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gopal Krishna, Head Operations | ||
| Michael Golembiewski, Chief Officer | ||
| Kimberly Farrand, Senior Operations | ||
| Raj JD, Chairman, Founder | ||
| Anthony Marciano, Chief Officer | ||
| Karen Fusaro, Senior Operations | ||
| Tim MD, Chief Officer |
Seelos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Seelos Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.84 | |||
| Return On Asset | -2.61 | |||
| Profit Margin | 2.03 % | |||
| Operating Margin | (8.35) % | |||
| Current Valuation | 10.45 M | |||
| Shares Outstanding | 581 K | |||
| Shares Owned By Insiders | 0.49 % | |||
| Shares Owned By Institutions | 4.46 % | |||
| Number Of Shares Shorted | 170.89 K | |||
| Price To Book | 15.10 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in income. Note that the Seelos Therapeutics information on this page should be used as a complementary analysis to other Seelos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Seelos OTC Stock
If you are still planning to invest in Seelos Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Seelos Therapeutics' history and understand the potential risks before investing.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |